DOCSLIB.ORG

Difluorodeoxyguanosine in Chinese Hamster Ovary Cells'

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Difluorodeoxyguanosine in Chinese Hamster Ovary Cells' [CANCER RESEARCH55, 1517-1524, April 1, 19951 Cytotoxicity, Metabolism, and Mechanisms of Action of 2',2'- Difluorodeoxyguanosine in Chinese Hamster Ovary Cells' Varsha Gandhi,2 Shin Mineishi, Peng Huang, Amy J. Chapman, Yandan Yang, Feng Chen, Biffie Nowak, Shern Chubb, Larry W. Hertel, and William Plunkett Department of Clinical Investigation, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030 (V. G., S. M., P. H.. A. J. C.. Y. 1'., F. C., B. N., S. C., w. p.]. andLillyResearchLaboratories,Indianapolis,indiana46285(L W.H.) ABSTRACT treatment of hematological malignancies (4—6).Arabinosyladenine, although not successful in cancer therapy, has proven antiviral activity The emerging clinical success of gemcItabine (2',2'-difluorodeoxycytl dine) Stimulated interest in the synthesis and evaluation of purine conge (7). The importance of the 2'-pentose moiety for the design of chemo ners. The cytotoxicity, metabolism, and mechanisms of action of the lead therapeutic agents and the fact that fluorine has a van der Waals radius candidate, 2',2'-difluorodeoxyguanoslne (dFdGuo), were StUdied In ChI nese hamster ovary cells Unlike the natural nucleoside deoxyguanosine similar to that of hydrogen led to the synthesis and evaluation of (dGuo), dFdGuo was not a substrate for purine nucleoside phosphorylase 2'-fluorinated analogues. 2'-Deoxy-2'-fluorocytidine and 2'-deoxy Wild-type Chinese hamster ovary cells and a mutant line deficient in 2'-fluoroguanosine possess inhibitory activities against several deoxycytidine (dCyd) kinase were similarly affected by dFdGuo (50% lymphoid cell lines and influenza viruses, respectively (8, 9). Inter inhibitory concentration, 7.5 and 6.5 pM, respectively), suggesting that estingly, substitution of the 2'-hydrogen of dCyd3 with a fluorine unlike gemcitabine, dCyd kinase was not responsible for activation of atom in the arabinose configuration produced 10-fold greater cyto dFdGuo This was further confirmed by separation of nucleoside kinases toxicity than when placed in the ribose position (10). 2'-Fluoroarabi (adenosine kinase, dGuo ldnase, and dCyd kinase) of Chinese hamster nosylguanine is active against human leukemia cells in vitro (11). ovary cells on DEAE-cellulose column chromatography. The kinase ac Recently, substitution of both hydrogens of the 2'-carbon of dCyd tivity that phosphorylated dGuo also converted dFdGuo to its monophos. with fluorines generated dFdCyd (12), which is currently being phate, suggesting that dGuo kinase activated dFdGuo. Consistent with this result, coincubation with dGuo spared the dFdGuo-mediated toxicity; evaluated in the clinic under the generic name gemcitabine. however, addition of up to 10 mM dCyd did not reverse the toxicity of Comparative studies between ara-C and dFdCyd demonstrated that dFdGuo. Intracellularly, dFdGuo was phosphorylated to its mono-, di-, the difluoro anomer is transported more rapidly into cells and is a and triphosphates; dFdGuo triphosphate (dFdGTP) was the major me preferred substrate for phosphorylation to the active 5'-triphosphate, tabolite and accumulated to 45 jiM after a 6-h Incubation with 30 jaM which is relatively stable in cells (i3). Additionally, unlike ara-C, the dFdGuo. The elimination of dFdGTP was monophasic with a t½ofabout diphosphate of dFdCyd inhibited ribonucleotide reductase, an action 6 h. Deoxynucleotides were decreased in cells Incubated with dFdGuo, that decreased deoxynucleotide pools and was the key to the suggesting that ribonudeotide reductase was Inhibited. dAT?, which de self-potentiation of the analogue (14—16). creased 78% after a 4-h Incubation with 30 jaM dFdGuo, was most This multitude of actions of gemcitabine metabolites in exerting affected@dFdGuo was a potent inhibitor of DNA synthesis. Extension of a DNA printer over a defined template in the presence of dFdGTP revealed cytotoxicity and its emerging clinical success (17) stimulated interest that dFdGTP was a good substrate for incorporation opposite C sites of in the synthesis and evaluation of purine congeners (18, 19). Meta the template by DNA polymerase a dFdGTP incorporation caused DNA bolic inactivation and growth inhibition studies in a variety of tumor polymerase a to pause after the polymerization of one additional de lines suggested that dFdGuo (Fig. 1) was the lead analogue among the oxynucleotide. This pattern oflnhlbltlon, which is shared by gemcltabine, purine series (18, 19). Using CHO cells, we investigated the cytotox distinguishes 2',2'-difluoronucleosldes from arabinosylnudeosides which icity, metabolism, and mechanisms of action of dFdGuo. Emphasis is halt primer extension at the Incorporation slte dGTP competed effectively placed on the enzymes likely to be involved in the catabolism (purine with dFdGTP for incorporation by DNA polymerase a The unique nucleoside phosphorylase) and anabolism (nucleoside kinases) of activation requirements and patterns of Inhibition of DNA synthesis din dFdGuo and on ribonucleotide reductase and DNA polymerase, which tinguish this promising new antimetaboilte from other nucleoside by analogy with dFdCyd are likely targets of dFdGuo nucleotides. The analogues. results are compared with those of dFdCyd and the base congener ara-G. INTRODUCTION MATERIALS AND METHODS The chemical constituents and their configuration at the 2'-position of purine and pynmidine nucleotides are critical determinants of the Chemicals. dFdGuo, its 5'-triphosphate, dFdGTP, and dFdlno were syn metabolic fate and therapeutic activity of these nucleic acid precur thesized at the Lilly Research Laboratories, Indianapolis, IN. [8-3HJdFdGuo sors. A hydroxyl group in the arabinose configuration results in the (specific activity, 6 Ci/mmol) was prepared by Amersham Radiochemicals, incorporation of these arabinosyl nucleosides into DNA and inhibition Arlington, IL. Bovine spleen purine nucleoside phosphorylase was purchased of further DNA synthesis, leading to cell death (1—3).Arabinosyl from Sigma Chemical Co., St. Louis, MO, as were natural nucleosides and analogues of both purine and pyrimidine are established agents in the nucleotides. All other chemicals were of the highest purity available. For nucleoside kinase assays, the natural nucleosides [2,8-3H]adenosine(39 Ci/mmol), [5-3H]dCyd (26 Ci/mmol), and [8-3H]dGuo (7 Ci/mmol) were Received 11/29/94; accepted 2/3/95. Thecostsof publicationofthisarticleweredefrayedinpartby thepaymentofpage charges. This article must therefore be hereby marked advertisement in accordance with 3 The abbreviations used are: dCyd, deoxycitidine; dAdo, deoxyadenosine; ara-C and 18 U.S.C. Section 1734 solely to indicate this fact. ara-cm', 1-@-t-arabinofuranosylcytosineandits 5'-triphosphate;ara-Gand ara-GTP, 1 Supported in part by Grants CA 28596 and CA 57629 from the National Cancer i-@-D-arabinofuranosylguanine and its 5'-triphosphate; dFdCyd, dFdCMP, dFdCDP, and Institute, Department of Health and Human Services, and Grant DHP-1 from the Amer dFdCFP, 2',2'-difluorodeoxycytidine (gemcitabine) and its 5'-mono-, -di-, and -triphos icanCancerSociety. phate;dFdGuo,dFdGMP,dFdGDP,anddFdGTP,2',2'-difluorodeoxyguanosineandits 2 To whom requests for reprints should be addressed, at Department of Clinical 5'-mono-, -di-, and -triphosphate; dGuo, deoxyguanosine; dFdlno, difluorodeoxyinosine; Investigation, Box 52, The University of Texas M. D. Anderson Cancer Center, Houston, PNP, purine nucleoside phosphorylase; t@, half-life of elimination; dNTP, deoxynucle TX 77030. otide triphosphate; CHO, Chinese hamster ovary; pol a, polymerase a. 1517 Downloaded from cancerres.aacrjournals.org on September 24, 2021. © 1995 American Association for Cancer Research. METABOUSM AND ACtiONS OF DIFLUORODEOXYGUANOSINE purchased from ICN Biochemicals (Costa Mesa, CA). All nucleosides were 0 purified by reverse-phase HPLC to greater than 99% purity. Cell CUltUre and Cytotoxicity. CHO cell lines were maintained in loga rithmic growth on 60-mm plastic dishes or roller bottles in McCoy's 5A H2N@5@> medium with 20% horse serum (GIBCO, Grand Island, NY). Under these conditions, the cell population-doubling time was 12 h. The cell line aC'@7, HO@ Ho@c::@ kindly supplied by Priscilla P. Saunders (20), is a CHO line deficient in dCyd kinase. In several experiments, cells were trypsinized, washed into calcium free McCoy's 5A medium, and grown in spinner flasks for 24 to 36 h before OH F use. Clonogenicity after drug treatment was determined by two methods. In the Deoxyguanoslrss Difluorodooxyguano first, cells were seeded on plates, treated as indicated, washed into fresh (dGuo) (dFdG) medium, and incubated for 5 days to allow colony formation. In the second procedure, cells were incubated with drugs in suspension culture. At the Fig. 1. Chemical structures of dGuo and dFdOuo (dFdG). indicated times portions of each culture were removed, washed into drug-free medium, plated in multiple dilutions at densities of 100—1000cells/plate,and incubated for 7—8days. Colonies were fixed and stained with methanol calculation assumes that nucleotides are uniformly distributed in total cell containing 0.5% crystal violet. The mean of at least 3 plates was determined; water. SD values were less than 10% of the mean in every case. Determinations ofdNTP. CHO cells incubated with 10 or 30 g@MdFdGuo Phosphorolysis of dFdGuo. The activity of PNP was determined by for 3 h were extracted by 60% methanol. The DNA polymerase assay as spectrophotometric assay. Normal substrates guanosine and inosine at 10, 20, modified
Load more
Loading...
Loading...
Loading...
Loading...
Loading...

4 pages remaining, click to load more.

Recommended publications
  • The Regulation of Carbamoyl Phosphate Synthetase-Aspartate Transcarbamoylase-Dihydroorotase (Cad) by Phosphorylation and Protein-Protein Interactions
    THE REGULATION OF CARBAMOYL PHOSPHATE SYNTHETASE-ASPARTATE TRANSCARBAMOYLASE-DIHYDROOROTASE (CAD) BY PHOSPHORYLATION AND PROTEIN-PROTEIN INTERACTIONS Eric M. Wauson A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Pharmacology. Chapel Hill 2007 Approved by: Lee M. Graves, Ph.D. T. Kendall Harden, Ph.D. Gary L. Johnson, Ph.D. Aziz Sancar M.D., Ph.D. Beverly S. Mitchell, M.D. 2007 Eric M. Wauson ALL RIGHTS RESERVED ii ABSTRACT Eric M. Wauson: The Regulation of Carbamoyl Phosphate Synthetase-Aspartate Transcarbamoylase-Dihydroorotase (CAD) by Phosphorylation and Protein-Protein Interactions (Under the direction of Lee M. Graves, Ph.D.) Pyrimidines have many important roles in cellular physiology, as they are used in the formation of DNA, RNA, phospholipids, and pyrimidine sugars. The first rate- limiting step in the de novo pyrimidine synthesis pathway is catalyzed by the carbamoyl phosphate synthetase II (CPSase II) part of the multienzymatic complex Carbamoyl phosphate synthetase, Aspartate transcarbamoylase, Dihydroorotase (CAD). CAD gene induction is highly correlated to cell proliferation. Additionally, CAD is allosterically inhibited or activated by uridine triphosphate (UTP) or phosphoribosyl pyrophosphate (PRPP), respectively. The phosphorylation of CAD by PKA and ERK has been reported to modulate the response of CAD to allosteric modulators. While there has been much speculation on the identity of CAD phosphorylation sites, no definitive identification of in vivo CAD phosphorylation sites has been performed. Therefore, we sought to determine the specific CAD residues phosphorylated by ERK and PKA in intact cells.
    [Show full text]
  • DHFR Inhibitors: Reading the Past for Discovering Novel Anticancer Agents
    molecules Review DHFR Inhibitors: Reading the Past for Discovering Novel Anticancer Agents Maria Valeria Raimondi 1,*,† , Ornella Randazzo 1,†, Mery La Franca 1 , Giampaolo Barone 1 , Elisa Vignoni 2, Daniela Rossi 2 and Simona Collina 2,* 1 Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, via Archirafi 32, 90123 Palermo, Italy; ornella.randazzo01@unipa.it (O.R.); mery.lafranca@unipa.it (M.L.F.); giampaolo.barone@unipa.it (G.B.) 2 Drug Sciences Department, Medicinal Chemistry and Pharmaceutical Technology Section, University of Pavia, via Taramelli 12, 27100 Pavia, Italy; elisa.vignoni01@universitadipavia.it (E.V.); daniela.rossi@unipv.it (D.R.) * Correspondence: mariavaleria.raimondi@unipa.it (M.V.R.); simona.collina@unipv.it (S.C.); Tel.: +390-912-389-1915 (M.V.R.); +390-382-987-379 (S.C.) † These Authors contributed equally to this work. Academic Editors: Simona Collina and Mariarosaria Miloso Received: 25 February 2019; Accepted: 20 March 2019; Published: 22 March 2019 Abstract: Dihydrofolate reductase inhibitors are an important class of drugs, as evidenced by their use as antibacterial, antimalarial, antifungal, and anticancer agents. Progress in understanding the biochemical basis of mechanisms responsible for enzyme selectivity and antiproliferative effects has renewed the interest in antifolates for cancer chemotherapy and prompted the medicinal chemistry community to develop novel and selective human DHFR inhibitors, thus leading to a new generation of DHFR inhibitors. This work summarizes the mechanism of action, chemical, and anticancer profile of the DHFR inhibitors discovered in the last six years. New strategies in DHFR drug discovery are also provided, in order to thoroughly delineate the current landscape for medicinal chemists interested in furthering this study in the anticancer field.
    [Show full text]
  • 1611 REGULATION of PYRIMIDINE METABOLISM in PLANTS Chris
    [Frontiers in Bioscience 9, 1611-1625, May 1, 2004] REGULATION OF PYRIMIDINE METABOLISM IN PLANTS 1, 2 1, 3 1, 4 1, 5 1, 6 1, 7 Chris Kafer , Lan Zhou , Djoko Santoso , Adel Guirgis , Brock Weers , Sanggyu Park and Robert Thornburg 1 1 Department of Biochemistry, Biophysics, and Molecular Biology, Iowa State University, Ames, Iowa 50011, 2 BASF Plant Science LLC, 2901 South Loop Drive, Ste 3800, Ames, Iowa 50014, 3 Lan Zhou, Pioneer Hi-Bred International, Inc. 7300 NW 62nd Avenue, PO Box 1004, Johnston, Iowa 50131-1004, 4 Indonesian Biotechnology Research Institute for Estate Crops, Jl, Taman Kencana No 1, Bogor 16151 Indonesia, 5 Institute of Genetic Engineering and Biotechnology, Menofiya University, PO Box 79/22857, Sadat City, Egypt, 6 Department of Biochemistry, University of Iowa, 4/511 Bowen Science Building, Iowa City, Iowa 52242-1109, 7 Division of Life and Environment, College of Natural Resources, Daegu University, Gyongsan City, Gyongbuk, Korea 712-714 TABLE OF CONTENTS 1. Abstract 2. Introduction 3. Pyrimidine metabolic pathways 3.1. De novo pyrimidine biosynthesis 3.1.1. CPSase 3.1.2. ATCase 3.1.3. DHOase 3.1.4. DHODH 3.1.5. UMPS 3.1.6. Intracellular Organization of the de novo Pathway 3.2. Pyrimidine Salvage and Recycling 3.2.1. Cytosine deaminase 3.2.2. Cytidine deaminase 3.2.3. UPRTase 3.3. Pyrimidine Modification 3.3.1. UMP/CMP kinase 3.3.2. NDP kinase 3.3.3. CTP synthase, NDP reductase, dUTPase 3.3.4. Thymidylate synthase/Dihydrofolate reductase 3.4. Pyrimidine Catabolism 4. Regulation of pyrimidine metabolism 4.1.
    [Show full text]
  • TITLE Adenylate Kinase 2 Deficiency Causes NAD+ Depletion and Impaired Purine Metabolism During Myelopoiesis
    bioRxiv preprint doi: https://doi.org/10.1101/2021.07.05.450633; this version posted July 6, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. TITLE Adenylate Kinase 2 deficiency causes NAD+ depletion and impaired purine metabolism during myelopoiesis AUTHORS Wenqing Wang1, Andew DeVilbiss2, Martin Arreola1, Thomas Mathews2, Misty Martin-Sandoval2, Zhiyu Zhao2, Avni Awani1, Daniel Dever1, Waleed Al-Herz3, Luigi Noratangelo4, Matthew H. Porteus1, Sean J. Morrison2, Katja G. Weinacht1, * 1. Department of Pediatrics, Stanford University School of Medicine, Stanford, California 94305 USA 2. Children’s Research Institute, University of Texas Southwestern Medical Center, Dallas, Texas 75390 USA 3. Department of Pediatrics, Faculty of Medicine, Kuwait University, Safat, 13110 Kuwait 4. Laboratory of Clinical Immunology and Microbiology, National Institute of Health, BETHESDA MD 20814 USA * Corresponding author ABSTRACT Reticular Dysgenesis is a particularly grave from of severe combined immunodeficiency (SCID) that presents with severe congenital neutropenia and a maturation arrest of most cells of the lymphoid lineage. The disease is caused by biallelic loss of function mutations in the mitochondrial enzyme Adenylate Kinase 2 (AK2). AK2 mediates the phosphorylation of adenosine monophosphate (AMP) to adenosine diphosphate (ADP) as substrate for adenosine triphosphate (ATP) synthesis in the mitochondria. Accordingly, it has long been hypothesized that a decline in OXPHOS metabolism is the driver of the disease. The mechanistic basis for Reticular Dysgenesis, however, remained incompletely understood, largely due to lack of appropriate model systems to phenocopy the human disease.
    [Show full text]
  • NADPH Homeostasis in Cancer: Functions, Mechanisms and Therapeutic Implications
    Signal Transduction and Targeted Therapy www.nature.com/sigtrans REVIEW ARTICLE OPEN NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications Huai-Qiang Ju 1,2, Jin-Fei Lin1, Tian Tian1, Dan Xie 1 and Rui-Hua Xu 1,2 Nicotinamide adenine dinucleotide phosphate (NADPH) is an essential electron donor in all organisms, and provides the reducing power for anabolic reactions and redox balance. NADPH homeostasis is regulated by varied signaling pathways and several metabolic enzymes that undergo adaptive alteration in cancer cells. The metabolic reprogramming of NADPH renders cancer cells both highly dependent on this metabolic network for antioxidant capacity and more susceptible to oxidative stress. Modulating the unique NADPH homeostasis of cancer cells might be an effective strategy to eliminate these cells. In this review, we summarize the current existing literatures on NADPH homeostasis, including its biological functions, regulatory mechanisms and the corresponding therapeutic interventions in human cancers, providing insights into therapeutic implications of targeting NADPH metabolism and the associated mechanism for cancer therapy. Signal Transduction and Targeted Therapy (2020) 5:231; https://doi.org/10.1038/s41392-020-00326-0 1234567890();,: BACKGROUND for biosynthetic reactions to sustain their rapid growth.5,11 This In cancer cells, the appropriate levels of intracellular reactive realization has prompted molecular studies of NADPH metabolism oxygen species (ROS) are essential for signal transduction and and its exploitation for the development of anticancer agents. cellular processes.1,2 However, the overproduction of ROS can Recent advances have revealed that therapeutic modulation induce cytotoxicity and lead to DNA damage and cell apoptosis.3 based on NADPH metabolism has been widely viewed as a novel To prevent excessive oxidative stress and maintain favorable and effective anticancer strategy.
    [Show full text]
  • TRACE: Tennessee Research and Creative Exchange
    University of Tennessee, Knoxville TRACE: Tennessee Research and Creative Exchange Doctoral Dissertations Graduate School 8-2009 Structure-Function Studies of the Large Subunit of Ribonucleotide Reductase from Homo sapiens and Saccharomyces cerevisiae James Wesley Fairman University of Tennessee - Knoxville Follow this and additional works at: https://trace.tennessee.edu/utk_graddiss Part of the Biochemistry, Biophysics, and Structural Biology Commons Recommended Citation Fairman, James Wesley, "Structure-Function Studies of the Large Subunit of Ribonucleotide Reductase from Homo sapiens and Saccharomyces cerevisiae. " PhD diss., University of Tennessee, 2009. https://trace.tennessee.edu/utk_graddiss/49 This Dissertation is brought to you for free and open access by the Graduate School at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Doctoral Dissertations by an authorized administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact trace@utk.edu. To the Graduate Council: I am submitting herewith a dissertation written by James Wesley Fairman entitled "Structure- Function Studies of the Large Subunit of Ribonucleotide Reductase from Homo sapiens and Saccharomyces cerevisiae." I have examined the final electronic copy of this dissertation for form and content and recommend that it be accepted in partial fulfillment of the equirr ements for the degree of Doctor of Philosophy, with a major in Biochemistry and Cellular and Molecular Biology. Chris G. Dealwis,
    [Show full text]
  • Erythrocyte Metabolism in Purine Nucleoside Phosphorylase Deficiency After Enzyme Replacement Therapy by Infusion of Erythrocytes
    Erythrocyte metabolism in purine nucleoside phosphorylase deficiency after enzyme replacement therapy by infusion of erythrocytes. G E Staal, … , S K Wadman, D W Martin J Clin Invest. 1980;65(1):103-108. https://doi.org/10.1172/JCI109639. Research Article Purine nucleoside phosphorylase deficiency is associated with a severely defective T-cell immunity. A patient with purine nucleoside phosphorylase deficiency was treated with transfusions of irradiated erythrocytes and plasma. This resulted in a remarkable correction of the metabolic disturbances in the patient. The urinary excretion of inosine, deoxyinosine, guanosine, and deoxyguanosine decreased, whereas uric acid excretion as well as serum uric acid concentration increased. It could be shown that the enzyme activity of the circulating erythrocytes correlated inversely with the urinary excretion of nucleosides and directly with the excretion of uric acid. As a consequence of the therapy, several glycolytic intermediates of the erythrocytes were increased, especially 2,3-diphosphoglycerate. The high 2,3-diphosphoglycerate level caused a shift to the right of the oxygen dissociation curve (P50 = 32.9 mm Hg). The immunological status of the patient showed definite improvement after the enzyme replacement therapy. Find the latest version: https://jci.me/109639/pdf Erythrocyte Metabolism in Purine Nucleoside Phosphorylase Deficiency after Enzyme Replacement Therapy by Infusion of Erythrocytes GERARD E. J. STAAL, JAN W. STOOP, BEN J. M. ZEGERS, Louis H. SIEGENBEEK VAN HEUKELOM, MARGREET
    [Show full text]
  • Transient State Analysis of Porcine Dihydropyrimidine Dehydrogenase Reveals Reductive Activation by NADPH
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
    [Show full text]
  • ANABOLISM III: Biosynthesis Amino Acids & Nucleotides
    BI/CH 422/622 ANABOLISM OUTLINE: Photosynthesis Carbohydrate Biosynthesis in Animals Biosynthesis of Fatty Acids and Lipids Biosynthesis of Amino Acids and Nucleotides Nitrogen fixation nitrogenase Nitrogen assimilation Glutamine synthetase Glutamate synthase Amino-acid Biosynthesis non-essential essential Nucleotide Biosynthesis RNA precursors purines pyrimidines DNA precursors deoxy-nucleotides Biosynthesis of secondary products of amino acids ANABOLISM III: Biosynthesis Amino Acids & Nucleotides Dr. Kornberg: Lecture 04.26.17 (0:00-5:06) 5 min 1 Biosynthesis Amino Acids & Nucleotides How are Ribonucleic Acid Precursors So far: converted to Deoxyribonucleic Acid GMPàGDPàGTP Precursors? ….....and how is dTTP made? AMPàADPàATP 2’C-OH bond is directly reduced to 2’-H UMPàUDPàUTPà bond …without activating the carbon for CDPßCTP dehydration, etc.! catalyzed by ribonucleotide reductase Specific kinases, Non-specific kinase, e.g., UMP kinase, nucleoside GMP kinase, diphosphate kinase Very unique enzyme in all of biochemistry – use of free Adenylate kinase (works on both oxy- and radicals etc. deoxy-ribose GDPàdGDP nucleosides) Mechanism: Two H atoms are donated ADPàdADP by NADPH and carried by thioredoxin or glutaredoxin to the active site. UDPàdUDP –Substrates are the NDPs and the products CDPàdCDP are dNDP. Biosynthesis Amino Acids & Nucleotides Source of Reducing Structure of Ribonucleotide Reductase a2 are regulatory Electrons for and half the Ribonucleotide catalytic site; need to be reduced. Reductase b 2 are the other half (a b ) of the active site, 2 2 and the free- radical generators • NADPH serves as the electron donor. • Funneled through glutathione or JoAnne Stubbe thioredoxin pathways (1946– ) 2 •Most forms of enzyme have two catalytic/ regulatory subunits and two radical- generating subunits.
    [Show full text]
  • Genetic Factors Influencing Pyrimidine- Antagonist Chemotherapy
    The Pharmacogenomics Journal (2005) 5, 226–243 & 2005 Nature Publishing Group All rights reserved 1470-269X/05 $30.00 www.nature.com/tpj REVIEW Genetic factors influencing Pyrimidine- antagonist chemotherapy JG Maring1 ABSTRACT 2 Pyrimidine antagonists, for example, 5-fluorouracil (5-FU), cytarabine (ara-C) HJM Groen and gemcitabine (dFdC), are widely used in chemotherapy regimes for 2 FM Wachters colorectal, breast, head and neck, non-small-cell lung cancer, pancreatic DRA Uges3 cancer and leukaemias. Extensive metabolism is a prerequisite for conversion EGE de Vries4 of these pyrimidine prodrugs into active compounds. Interindividual variation in the activity of metabolising enzymes can affect the extent of 1Department of Pharmacy, Diaconessen Hospital prodrug activation and, as a result, act on the efficacy of chemotherapy Meppel & Bethesda Hospital Hoogeveen, Meppel, treatment. Genetic factors at least partly explain interindividual variation in 2 The Netherlands; Department of Pulmonary antitumour efficacy and toxicity of pyrimidine antagonists. In this review, Diseases, University of Groningen & University Medical Center Groningen, Groningen, The proteins relevant for the efficacy and toxicity of pyrimidine antagonists will Netherlands; 3Department of Pharmacy, be summarised. In addition, the role of germline polymorphisms, tumour- University of Groningen & University Medical specific somatic mutations and protein expression levels in the metabolic Center Groningen, Groningen, The Netherlands; pathways and clinical pharmacology
    [Show full text]
  • Genome-Wide Transcriptional Analysis of Carboplatin Response in Chemosensitive and Chemoresistant Ovarian Cancer Cells
    1605 Genome-wide transcriptional analysis of carboplatin response in chemosensitive and chemoresistant ovarian cancer cells David Peters,1,2 John Freund,2 and Robert L. Ochs2 variety of disease processes, including cancer. Patterns of global gene expression can reveal the molecular pathways 1 Department of Pharmacology and Therapeutics, University of relevant to the disease process and identify potential new Liverpool, United Kingdom and 2Precision Therapeutics, Inc., Pittsburgh, Pennsylvania therapeutic targets. The use of this technology for the molecular classification of cancer was recently shown with the identification of an expression profile that was Abstract predictive of patient outcome for B-cell lymphoma (1). We have recently described an ex vivo chemoresponse In addition, this study showed that histologically similar assay for determining chemosensitivity in primary cultures tumors can be differentiated based on their gene expression of human tumors. In this study, we have extended these profiles. Ultimately, these unique patterns of gene expres- experiments in an effort to correlate chemoresponse data sion may be used as guidelines to direct different modes of with gene expression patterns at the level of transcription. therapy. Primary cultures of cells derived from ovarian carcinomas Although it is widely recognized that patients with the of individual patients (n = 6) were characterized using same histologic stage and grade of cancer respond to the ChemoFx assay and classified as either carboplatin therapies differently, few clinical tests can predict indi- sensitive (n = 3) or resistant (n = 3). Three representa- vidual patient responses. The next great challenge will be tive cultures of cells from each individual tumor were then to use the power of post-genomic technology, including subjected to Affymetrix gene chip analysis (n = 18) using microarray analyses, to correlate gene expression patterns U95A human gene chip arrays.
    [Show full text]
  • S Phase-Specific Synthesis of Dihydrofolate Reductase in Chinese Hamster Ovary Cells (Cell Cycle/Methotrexate-Resistance/Fluorescence-Activated Cell Sorter) BRIAN D
    Proc. NatL Acad. Sci. USA Vol. 78, No. 8, pp. 4985-4989, August 1981 Cell Biology S phase-specific synthesis of dihydrofolate reductase in Chinese hamster ovary cells (cell cycle/methotrexate-resistance/fluorescence-activated cell sorter) BRIAN D. MARIANI, DoRis L. SLATE*, AND ROBERT T. SCHIMKEt Department of Biological Sciences, Stanford University, Stanford, California 94305 Contributed by Robert T. Schimke, April 20, 1981 ABSTRACT We investigated the cell cycle modulation ofdihy- DHFR content in MTX-resistant mouse 3T6 fibroblasts when drofolate reductase (DHFR; tetrahydrofolate dehydrogenase, serum-deprived cells were induced to reenter the cell cycle as 7,8-dihydroxyfolate:NADP+ oxidoreductase, EC 1.5.1.3) levels in a result of serum replenishment. Although this phenomenon methotrexate-resistant Chinese hamster ovary cells synchronized of a phase transition from a metabolically quiescent state to a by mitotic selection. DNA content and DHFR concentration were state of active proliferation has clear physiological significance analyzed throughout the cell cycle by standard biochemical tech- (1), our investigation focused on the modulation ofDHFR levels niques and by double fluorescence staining utilizing the fluores- within the framework ofa single, physiologically continuous cell cence-activated cell sorter. We found an S phase-specific period cycle. of DHFR biosynthetic activity. Commencing within hour 2 of S We achieved precise cell cycle synchrony by the selection phase and continuing throughout the duration of S phase, there is a 90% increase in DHFR specific activity. This results from an of mitotic cells from exponentially growing monolayers. We "=2.5-fold increase in the level of DHFR, while total soluble pro- determined the specific activity of DHFR throughout the cell tein increases 50% during the same period.
    [Show full text]